Medpace (MEDP) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Medpace (MEDP) closed at $339.05, marking a +0.52% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.73%. Meanwhile, the Dow gained 0.16%, and the Nasdaq, a tech-heavy index, added 0.98%.Coming into today, shares of the provider of outsourced clinical development services had lost 0.14% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 0.34%.The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is predicted to post an EPS of $2.97, indicating a 20.73% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $536.37 million, indicating a 7.62% upward movement from the same quarter last year.For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.93 per share and a revenue of $2.11 billion, signifying shifts of +34.35% and +11.82%, respectively, from the last year.Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Medpace. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Medpace boasts a Zacks Rank of #3 (Hold).Valuation is also important, so investors should note that Medpace has a Forward P/E ratio of 28.27 right now. This represents a premium compared to its industry's average Forward P/E of 16.87.Investors should also note that MEDP has a PEG ratio of 1.8 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services was holding an average PEG ratio of 1.48 at yesterday's closing price.The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 130, putting it in the bottom 49% of all 250+ industries.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medpace Holdings, Inc. (MEDP): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks